Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Stefan K. Barta, MD, MS, MRCPCUK

Stefan K. Barta, MD, MS, MRCPCUK Physician

Associate Professor of Clinical Medicine

Dr. Barta is employed by Penn Medicine.

Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

Clinical Specialties

Specialty:

  • Hematology

Programs & Centers:

Board Certification:

  • Hematology, 2010
  • Medical Oncology, 2010

Clinical Expertise:

  • Autologous Stem Cell Transplantation
  • Chronic Lymphocytic Leukemia (CLL)
  • Cutaneous T-Cell Lymphoma
  • Lymphoma
  • Non-Hodgkin Lymphoma

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Johann Wolfgang Goethe University
Residency:
Fellowship:
Residency: Saint Luke's-Roosevelt Hospital Center
Fellowship: Albert Einstein - Montefiore Medical Center

Memberships

AIDS Malignancy Consortium, National American Society for Bone Marrow Transplantation (ASBMT), National American Society of Clinical Oncology, National American Society of Hematology, National Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN), National Lymphoma Research Foundation, Local

Hospital Affiliation

Dr. Barta is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Barta Stefan K, Zain Jasmine, MacFarlane Alexander W, Smith Sonali M, Ruan Jia, Fung Henry C, Tan Carlyn R, Yang Yibin, Alpaugh R Katherine, Dulaimi Essel, Ross Eric A, Campbell Kerry S, Khan Nadia, Siddharta Rawat, Fowler Nathan H, Fisher Richard I, Oki Yasuhiro: Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clinical lymphoma, myeloma & leukemia : 2019.

Gerson James N, Handorf Elizabeth, Villa Diego, Gerrie Alina S, Chapani Parv, Li Shaoying, Medeiros L Jeffrey, Wang Michael I, Cohen Jonathon B, Calzada Oscar, Churnetski Michael C, Hill Brian T, Sawalha Yazeed, Hernandez-Ilizaliturri Francisco J, Kothari Shalin, Vose Julie M, Bast Martin A, Fenske Timothy S, Narayana Rao Gari Swapna, Maddocks Kami J, Bond David, Bachanova Veronika, Kolla Bhaskar, Chavez Julio, Shah Bijal, Lansigan Frederick, Burns Timothy F, Donovan Alexandra M, Wagner-Johnston Nina: Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 37 (6): JCO1800690,2019.

Martin James M, Wu Hong, Barta Stefan K: CD30+ T-cell lymphoproliferative disorders. Chinese clinical oncology 8 (1): 4,2018.

Liu Yang, Barta Stefan Klaus: Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. American journal of hematology 94 (5): 604-616,2019.

Badar Talha, Hamadani Mehdi, Bachanova Veronika, Maddocks Kami J, Umyarova Elvira, Chavez Julio C, Epperla Narendranath, Chhabra Saurabh, Xavier Ana C, Karmali Reem, Salhab Mohammed, Reddy Nishitha, Glenn Martha J, Hernandez-Ilizaliturri Francisco J, Flowers Christopher R, Evens Andrew M, Zhou Zheng, Lansigan Frederick, Barta Stefan K, Cohen Jonathon B, Fenske Timothy S, Costa Luciano J: Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia & lymphoma 60 (4): 1-7,2018.

Tan CRC, Barta SK, Lee J, Rudek MA, Sparano JA, Noy A.: Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leuk Lymphoma 59 (8): 1851-1860,2018.

Reid Erin, Suneja Gita, Ambinder Richard F, Ard Kevin, Baiocchi Robert, Barta Stefan K, Carchman Evie, Cohen Adam, Gupta Neel, Johung Kimberly L, Klopp Ann, LaCasce Ann S, Lin Chi, Makarova-Rusher Oxana V, Mehta Amitkumar, Menon Manoj P, Morgan David, Nathwani Nitya, Noy Ariela, Palella Frank, Ratner Lee, Rizza Stacey, Rudek Michelle A, Taylor Jeff, Tomlinson Benjamin, Wang Chia-Ching J, Dwyer Mary A, Freedman-Cass Deborah A: Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 16 (8): 986-1017,2018.

Tan CRC, Abdul-Majeed S, Cael B, Barta SK.: Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet 58 (2): 157-168,2018.

Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H.: NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw 16 (2): 123-135,2018.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang M, Cohen JB, Calzada O, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, Fenske TM, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Lansigan F, Burns T, Donovan AD, Mehta A, Anderson JK, Reddy N, Kovach A, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach D, Evens A, Klein A, Barta SK.: Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era. American Society of Hematology Annual Meeting, San Francisco, CA : 2017.

Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, Harding J, Baydoun HH, Cheng X, Jacobson S.: Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer J. 25 (6): e408,2016.

Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS.: Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 122 (19): 2996-3004,2016.

Barta SK, Jain R, Mazumder A, Carter J, Almanzar L, Browne R, Shahnaz S, Elkind R, Kaminetzky D, Battini R, Derman O, Kornblum N, Verma A, Braunschweig I.: Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 17 (10): 650-657,2017.

Landsburg DJ, Ramchandren R, Oki Y, Pagel JM, Lugtennurg PJ, Gharavi R, Ma A, Hafeez A, Barta SK.: Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907. American Society of Hematology Annual Meeting, San Francisco, CA : 2017.

Academic Contact Info

Perelman Center
12th Floor, Room 12-177
3400 Civic Center Blvd

Philadelphia , PA 19104
Phone: (215) 615-6506
Patient appointments: 800-789-7366 (PENN)